Allarity Therapeutics CEO Letter to Shareholders: Read the letter from CEO James G. Cullem to Allarity’s shareholders and other stakeholders, published on August 11, 2023
Stenoparib is at the forefront of Allarity’s mission to personalize cancer care. Here’s why it’s our lead program:
Versatility: While our current Phase 2 study is focused on advancing stenoparib toward eventual approval in ovarian cancer, we believe the drug’s potential may extend to multiple cancer types, making it a versatile weapon against cancer.
Molecular model of Allarity’s lead asset: stenoparib
Allarity’s focused pipeline is centered on stenoparib, an orally available small molecule. Its unique dual-action mechanism inhibits both PARP1/2 and telomerase maintenance enzymes.
Our DRP® Technology is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond or not to a particular drug.
Results from our DRP® platform have been published in numerous peer-reviewed scientific journals, highlighting the predictive capabilities of our proprietary approach to precision medicine.
TBA
Copyright © 2024 Allarity Therapeutics, Inc. All Rights Reserved.
Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.